The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving ...

Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced the initiation of Part B of ...

SolidddVisionTM smartglasses, the first true vision correction for people living with vision loss due to macula ...

Oculis Holding’s OCS-05 phase 2 ACUITY trial in acute optic neuritis meets primary safety endpoint and key secondary efficacy endpoints: Zug, Switzerland Tuesday, January 7, 202 ...

SolidddVision smartglasses, which correct vision for people living with vision loss due to macular degeneration, will debut at CES.